Literature DB >> 34727184

Prevention of recurrent thrombotic events in children with central venous catheter-associated venous thrombosis.

Helen Havens Clark1, Lance Ballester1, Hilary Whitworth1, Leslie Raffini1, Char Witmer1.   

Abstract

Central venous catheters (CVC) are the most significant risk factor for pediatric venous thromboembolism (VTE). After an index CVC-associated VTE (CVC-VTE), the role of secondary prophylaxis for subsequent CVC placement is uncertain. Aims of this single-center retrospective study were to evaluate the efficacy of secondary prophylaxis for patients with a prior CVC-VTE and identify risk factors associated with recurrent VTE in patients less than 19 years with an index CVC-VTE between 2003 and 2013. Data collection included clinical and demographic factors, subsequent CVC placement, secondary prophylaxis strategy, recurrent VTE, and bleeding. Risk factors for recurrence and effectiveness of secondary prophylaxis were evaluated using survival and binomial models. Among 373 patients with an index CVC-VTE, 239 (64.1%) had subsequent CVC placement; 17.4% (65/373) of patients had recurrent VTE, of which 90.8% (59/65) were CVC-associated. On multivariable survival analysis, each additional CVC (hazards ratio [HR] 12.00; 95% confidence interval [CI] 2.78-51.91), congenital heart disease (HR 3.70; 95% CI 1.97-6.95), and total parenteral nutrition dependence (HR 4.02; 95% CI 2.23-7.28) were associated with an increased hazard of recurrence. Full dose anticoagulation for secondary prophylaxis was associated with decreased odds of recurrent CVC-VTE (odds ratio [OR] 0.35; 95% CI 0.19-0.65) but not prophylactic dosing (OR 0.61; 95% CI 0.28-1.30). Only 1.3% of CVCs experienced major bleeding with prophylactic or full-dose anticoagulation. In summary, children with CVC-VTE are at increased risk for recurrent VTE. Secondary prophylaxis with full-dose anticoagulation was associated with a 65% reduction in odds of thrombotic events.
© 2022 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2022        PMID: 34727184      PMCID: PMC8777201          DOI: 10.1182/blood.2021013453

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  21 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  A multi-institutional registry of pediatric hospital-acquired thrombosis cases: The Children's Hospital-Acquired Thrombosis (CHAT) project.

Authors:  Julie Jaffray; Arash Mahajerin; Guy Young; Neil Goldenberg; Lingyun Ji; Richard Sposto; Amy Stillings; Emily Krava; Brian Branchford
Journal:  Thromb Res       Date:  2017-12-01       Impact factor: 3.944

3.  A survey of pediatric hematology/oncology specialists regarding management of central line associated venous thrombosis.

Authors:  Char M Witmer; Emily Sauck; Leslie J Raffini
Journal:  Pediatr Blood Cancer       Date:  2016-12-01       Impact factor: 3.167

4.  Development and Implementation Results of a Venous Thromboembolism Prophylaxis Guideline in a Tertiary Care Pediatric Hospital.

Authors:  Arash Mahajerin; Emily C Webber; Jennifer Morris; Kathryn Taylor; Michele Saysana
Journal:  Hosp Pediatr       Date:  2015-01-01

5.  Systemic thromboembolism in children. Data from the 1-800-NO-CLOTS Consultation Service.

Authors:  Stefan Kuhle; Patricia Massicotte; Anthony Chan; Margaret Adams; Mohamed Abdolell; Gabrielle de Veber; Lesley Mitchell
Journal:  Thromb Haemost       Date:  2004-10       Impact factor: 5.249

6.  Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007.

Authors:  Leslie Raffini; Yuan-Shung Huang; Char Witmer; Chris Feudtner
Journal:  Pediatrics       Date:  2009-09-07       Impact factor: 7.124

7.  Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children.

Authors:  Julie Jaffray; Char Witmer; Sarah H O'Brien; Rosa Diaz; Lingyun Ji; Emily Krava; Guy Young
Journal:  Blood       Date:  2020-01-16       Impact factor: 22.113

8.  Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial.

Authors:  E Vincent S Faustino; Veronika Shabanova; Leslie J Raffini; Sarah B Kandil; Simon Li; Matthew G Pinto; Jill M Cholette; Sheila J Hanson; Marianne E Nellis; Cicero T Silva; Ranjit Chima; Anjali Sharathkumar; Kimberly A Thomas; Tara McPartland; Joana A Tala; Philip C Spinella
Journal:  Crit Care Med       Date:  2021-03-01       Impact factor: 9.296

Review 9.  Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism.

Authors:  Arash Mahajerin; Stacy E Croteau
Journal:  Front Pediatr       Date:  2017-04-10       Impact factor: 3.418

10.  Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.

Authors:  E Vincent S Faustino; Leslie J Raffini; Sheila J Hanson; Jill M Cholette; Matthew G Pinto; Simon Li; Sarah B Kandil; Marianne E Nellis; Veronika Shabanova; Cicero T Silva; Joana A Tala; Tara McPartland; Philip C Spinella
Journal:  Crit Care Med       Date:  2021-04-01       Impact factor: 9.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.